Hong Kong Pharmaceuticals & Biotech Profitable Climbers

WuXi XDC Cayman

Market Cap: HK$68.1b

An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.

Biocytogen Pharmaceuticals (Beijing)

Market Cap: HK$35.6b

A biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.

RemeGen

Market Cap: HK$63.2b

A biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.

CanSino Biologics

Market Cap: HK$13.6b

Develops, manufactures, and commercializes vaccines in the People’s Republic of China.

Innovent Biologics

Market Cap: HK$140.3b

A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally.

JBM (Healthcare)

Market Cap: HK$2.3b

An investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally.

Consun Pharmaceutical Group

Market Cap: HK$14.5b

Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.

Luye Pharma Group

Market Cap: HK$9.7b

Develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally.

Simcere Pharmaceutical Group

Market Cap: HK$29.8b

An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.